UBS Group Lowers Pfizer (NYSE:PFE) to Neutral
UBS Group Lowers Pfizer (NYSE:PFE) to Neutral
UBS Group lowered shares of Pfizer (NYSE:PFE – Get Rating) from a buy rating to a neutral rating in a research note published on Thursday, MarketBeat reports. They currently have $47.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $55.00.
據MarketBeat報道，在週四發佈的一份研究報告中，瑞銀集團將輝瑞(NYSE：PFE-GET評級)的股票評級從買入下調至中性。他們目前對這家生物製藥公司的股票設定了47.00美元的目標價，低於之前55.00美元的目標價。
Several other equities research analysts have also recently commented on the company. Bank of America cut Pfizer from a buy rating to a neutral rating and set a $60.00 target price on the stock. in a research note on Wednesday, January 4th. JPMorgan Chase & Co. set a $50.00 target price on Pfizer in a research note on Wednesday, January 18th. Barclays upped their price objective on Pfizer from $44.00 to $49.00 and gave the stock an equal weight rating in a research note on Wednesday, November 2nd. SVB Leerink upped their price objective on Pfizer from $48.00 to $49.00 and gave the stock a market perform rating in a research note on Thursday, November 3rd. Finally, StockNews.com initiated coverage on Pfizer in a research note on Wednesday, October 12th. They set a strong-buy rating on the stock. Seven analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and a consensus target price of $52.33.
其他幾位股票研究分析師最近也對該公司發表了評論。美國銀行將輝瑞的評級從買入下調至中性，併為該股設定了60.00美元的目標價。在1月4日星期三的一份研究報告中。摩根大通(JPMorgan Chase&Co.)在1月18日週三的一份研究報告中為輝瑞設定了50美元的目標價。11月2日週三，巴克萊在一份研究報告中將輝瑞的目標價從44.00美元上調至49.00美元，並給予該股同等權重的評級。11月3日，SVB Leerink在一份研究報告中將輝瑞的目標價從48.00美元上調至49.00美元，並給出了該股的市場表現評級。最後，StockNews.com在10月12日星期三的一份研究報告中開始了對輝瑞的報道。他們對該股設定了強力買入評級。七位分析師對該股的評級為持有，兩位分析師給出了買入評級，一位分析師對該公司股票發出了強烈的買入評級。根據MarketBeat.com的數據，該股目前的平均評級為持有，共識目標價為52.33美元。
Pfizer Trading Down 1.0 %
輝瑞股價下跌1.0%
NYSE:PFE opened at $43.79 on Thursday. Pfizer has a fifty-two week low of $41.44 and a fifty-two week high of $56.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.37. The stock has a market capitalization of $245.81 billion, a PE ratio of 8.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.67. The business's 50-day simple moving average is $49.45 and its 200-day simple moving average is $47.95.
紐約證交所：PFE週四開盤報43.79美元。輝瑞在52周低點為41.44美元，在52周高點為56.32美元。該公司的債務權益比為0.35，流動比率為1.59，速動比率為1.37。該股市值為2,458.1億美元，市盈率為8.42，市盈率為1.09，貝塔係數為0.67。該業務的50日簡單移動均線切入位在49.45美元，200日簡單移動均線切入位在47.95美元。
Pfizer Increases Dividend
輝瑞增加股息
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 3rd. Investors of record on Friday, January 27th will be paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, January 26th. This is a boost from Pfizer's previous quarterly dividend of $0.40. Pfizer's dividend payout ratio is 31.54%.
該公司最近還宣佈了季度股息，將於3月3日星期五支付。1月27日(星期五)登記在冊的投資者將獲得0.41美元的股息。這意味着年化股息為1.64美元，收益率為3.75%。本次股息除息日為1月26日(星期四)。這比輝瑞之前的季度派息0.40美元有所提振。輝瑞的派息比率為31.54%。
Institutional Inflows and Outflows
機構資金流入和流出
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. RB Capital Management LLC grew its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company's stock valued at $282,000 after buying an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its holdings in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company's stock valued at $1,868,000 after buying an additional 400 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company's stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in shares of Pfizer by 136.3% during the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company's stock worth $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% during the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company's stock worth $69,238,000 after purchasing an additional 79,887 shares in the last quarter. 67.62% of the stock is owned by institutional investors and hedge funds.
一些機構投資者和對衝基金最近增持或減持了PFE的股份。RB Capital Management LLC在第一季度增持輝瑞6.7%的股份。RB Capital Management LLC現在持有這家生物製藥公司5,446股股票，價值28.2萬美元，上個季度又購買了341股。鐵木財富管理有限責任公司。第一季度輝瑞的持有量增加了1.1%。鐵木財富管理有限責任公司。現在擁有36,081股這家生物製藥公司的股票，價值1,868,000美元，在上個季度又購買了400股。聯合銀行在第一季度增持了0.6%的輝瑞股票。聯合銀行現在擁有46,671股這家生物製藥公司的股票，價值2,416,000美元，上個季度又購買了290股。第一季度，Ergoeles LLC對輝瑞股票的持有量增加了136.3%。在上個季度增持了21,209股後，Ergoeles LLC現在擁有36,766股這家生物製藥公司的股票，價值1,903,000美元。最後，麥肯錫金融公司在第一季度增持了6.4%的輝瑞股票。麥肯錫金融公司(Mackenzie Financial Corp)目前持有這家生物製藥公司1,337,418股股票，價值69,238,000美元，此前該公司在上個季度又購買了79,887股票。67.62%的股票由機構投資者和對衝基金持有。
Pfizer Company Profile
輝瑞公司簡介
(Get Rating)
(獲取評級)
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
輝瑞是一家以研究為基礎的全球生物製藥公司。它在全球範圍內從事生物製藥產品的發現、開發、製造、營銷、銷售和分銷。該公司在發達和新興市場開展合作，推動健康、預防、治療和治療，挑戰最令人畏懼的疾病。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於輝瑞的研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
接受輝瑞日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對輝瑞及相關公司評級的每日簡明摘要。